Peritoneal Cancer
142
18
30
74
Key Insights
Highlights
Success Rate
83% trial completion
Published Results
40 trials with published results (28%)
Research Maturity
74 completed trials (52% of total)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 49/100
10.6%
15 terminated out of 142 trials
83.1%
-3.4% vs benchmark
12%
17 trials in Phase 3/4
54%
40 of 74 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 74 completed trials
Clinical Trials (142)
Outcomes After Secondary Cytoreductive Surgery With or Without Carboplatin Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Followed by Systemic Combination Chemotherapy for Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
A Clinical Trial of Raludotatug Deruxtecan (R-DXd) With or Without Bevacizumab in Participants With Ovarian Cancer Who Have Progressed During Treatment With PARP-inhibitors Treatment on First Line Maintenance (MK-5909-008/ENGOT-ov107/GOG-3142 / REJOICE-Ovarian05)
A Study of Raludotatug Deruxtecan With or Without Bevacizumab as First-Line Maintenance Treatment in Non-HRD-Positive Advanced Ovarian Cancer (MK-5909-006, (ENGOT-ov102/GOG-3141/ REJOICE-Ovarian 04)
Evaluate BL-M17D1 in Patients w/HER2-Expressing/Mutant Advanced or Metastatic Solid Tumors
Depression Treatment and Screening in Ovarian Cancer Patients
Using Aspirin to Improve Immunological Features of Ovarian Tumors
TRANScriptional Pathways Of Surgical Pain Modulated by Music Therapy Exposure (TRANSPOSE)
A Study of the Drug I131-Omburtamab in People With Desmoplastic Small Round Cell Tumors and Other Solid Tumors in the Peritoneum
An Evaluation of Maintenance Therapy Combination Mirvetuximab Soravtansine and Olaparib
ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer
Genomic BRCA and Extensive ovArian Cancer Testing
Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer
Trial of Pembrolizumab Following Weekly Paclitaxel for Platinum-resistant Ovarian, Fallopian Tube or Peritoneal Cancer
Microdevice In Ovarian, Fallopian Tube, And Peritoneal Cancer
Multi-Centre Observational Study of Maintenance Niraparib in Treatment of Ovarian CanceR
Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery
Study of Acute Normovolemic Hemodilution (ANH) in People With Ovarian Cancer Who Are Having Cytoreductive Surgery
A Phase II Study Of Nivolumab/ Bevacizumab/Rucaparib
Prospective Clinico-biological Database of Patients With Ovarian and/or Peritoneal and/or Fallopian Tube Carcinoma
Perioperative Systemic Therapy for Isolated Resectable Colorectal Peritoneal Metastases